Experimental AML Vaccine Extends Survival in Trial

Adults with high-risk acute myeloid leukemia saw median survival of 24 months on galinpepimut-S versus under 15 months on standard options in a phase 3 trial.

Updated on Nov. 17, 2026 in Cancer

Experimental AML Vaccine Extends Survival in Trial

Sellas Life Sciences announced that its experimental peptide vaccine galinpepimut-S met its primary endpoint in a phase 3 trial of patients with acute myeloid leukemia (AML), a fast-growing blood cancer, and the company plans an accelerated filing with the FDA.

Why it matters

AML patients who are at high risk of relapse have had limited options, and a therapy that extends median survival could reshape treatment conversations for this group if regulators agree. The result arrives as one of the first phase 3 readouts of a targeted vaccine in this setting, though it still requires regulatory review.

This phase 3 randomized trial enrolled 126 patients with AML and compared galinpepimut-S against best available therapy, including chemotherapy and Venclexta. The trial required 80 patient deaths before its final analysis, and the company reports a 41% reduction in risk of death with the vaccine.

The players

Sellas Life Sciences

A biopharmaceutical company developing targeted cancer immunotherapies, including galinpepimut-S for hematologic malignancies.

Memorial Sloan Kettering Cancer Center

A leading New York cancer hospital and research institution that licensed galinpepimut-S to Sellas and conducts major oncology research.

U.S. Food and Drug Administration

The federal agency that regulates drugs and biologics in the United States and reviews the accelerated filing for galinpepimut-S.

The details

Galinpepimut-S is a peptide vaccine that targets the WT1 protein, which is found at elevated levels in many AML cells. The trial enrolled patients who had reached complete remission or at least two remissions but still had not recovered platelet counts, a group at high risk of relapse. The vaccine is licensed from Memorial Sloan Kettering Cancer Center, and the FDA granted it orphan designation in 2023.

Timeline

  1. Late October 2026: the 80th patient death was reached, enabling the final analysis.

  2. November 2026: Sellas announced the phase 3 results.

  3. December 2026: Sellas will present SLS009 response and survival outcomes at the American Society of Hematology annual meeting.

Health Landscape

AML has long been treated with intensive chemotherapy, and patients who relapse or cannot tolerate intensive regimens face poor outcomes. A phase 3 signal for a targeted vaccine adds a new category of option to a field that has seen few advances in older patients.

If you or a family member has been diagnosed with AML, this result is worth discussing with your oncologist, especially if you have had relapses or are not a candidate for intensive chemotherapy. Clinical trial enrollment is one way to gain access to investigational therapies before any approval.

The takeaway

A targeted vaccine showing a 41% reduction in risk of death in a phase 3 AML trial is a notable early signal, though full regulatory review is still ahead. Patients interested in new options can ask their oncologist whether ongoing clinical trials are a fit.

What happens next

Sellas will present SLS009 response and survival outcomes at the American Society of Hematology annual meeting in December 2026, and an accelerated FDA filing is planned.

Further reading

For broader context on treatment advances, see our Cancer coverage.